Klonaza

Quick links to important sections

Klonaza

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Klonaza

Property Description
Active ingredient Clonixin, Phloroglucinol, Trimethylphloroglucinol
Form Oral tablet and Injectable solution
Pharmacological class Analgesic and Antispasmodic (FDC)
General purpose Relief of pain associated with smooth muscle spasm
Origin Synthetic drug

The Identity of Klonaza: A Dual-Action Combination

Klonaza is a synthetic drug defined as a fixed-dose combination (FDC) medicinal product used to alleviate discomfort involving both pain and muscle contraction. It is categorized as an Analgesic and Antispasmodic agent, functioning as a dual-action therapeutic agent. This specific formulation integrates two distinct types of pharmacological action into a single pharmaceutical preparation, a feature that is clinically recognized for its efficiency in complex pain management. The FDC approach allows Klonaza to address two components of discomfort simultaneously, targeting both the sensation of pain and the underlying smooth muscle tightness.

Active Ingredients, Origin, and Available Forms

The core of Klonaza is its tripartite composition, featuring three active ingredients (INN): Clonixin, Phloroglucinol, and Trimethylphloroglucinol. Clonixin is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) component, primarily contributing the peripheral analgesic effect. The remaining two compounds, Phloroglucinol and Trimethylphloroglucinol, act as the spasmolytic components, providing a direct smooth muscle relaxant action. This synthetic drug is supplied in two main pharmaceutical preparations for flexibility in its route of administration: the oral tablet and the injectable solution (ampoule) for intramuscular use.

Klonaza's General Therapeutic Purpose and Distinctive Focus

The overall general purpose of Klonaza is to manage discomfort where both severe pain and involuntary smooth muscle spasm are major factors. The combination of the NSAID component and the spasmolytic components is designed to deliver synergistic relief. This integrated action is specifically intended for situations requiring the simultaneous modulation of both sensation and underlying muscle tension, providing targeted relief where monotherapy agents may be insufficient.

What side effects are possible with Klonaza?

Possible Side Effects and Safety Information

The official safety information for Klonaza is structured around major risks and frequency-classified adverse reactions, based on government regulatory documentation (e.g., FDA, EMA).

Regulatory Boxed Warning and Serious Risks

Official labeling includes a Boxed Warning because of several critical safety issues:

  • Concomitant Opioid Use: Using Klonaza with opioids can result in profound sedation, respiratory depression, coma, and death.
  • Abuse, Misuse, Addiction, and Dependence: Use exposes individuals to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Continued use may lead to physical dependence, with abrupt discontinuation potentially precipitating life-threatening acute withdrawal reactions (e.g., seizures).
  • Suicidal Thoughts or Behavior: As an antiepileptic drug, Klonaza carries an increased risk of suicidal thoughts or behavior for any indication, as observed in pooled analyses of clinical trials.

Contraindications and Caution

Klonaza is contraindicated (must not be used) if there is a history of sensitivity to benzodiazepines, clinical evidence of significant liver disease, or acute narrow-angle glaucoma.

Caution is advised for elderly patients, as they are more susceptible to central nervous system effects, and for patients with chronic respiratory insufficiency.

Common Adverse Reactions

The most frequently reported adverse reactions, based on clinical trial data, are related to the Nervous System and include somnolence (drowsiness), ataxia (impaired coordination), fatigue, and dizziness. Other common reactions include depression and memory disturbance. These effects are often dose-related and may diminish with continued treatment.

Dose- and Exposure-Related Patterns

The risks of dependence and acute withdrawal are known to increase with longer treatment duration and higher daily dose.

Overdose and Emergency Response

Overdose and when to seek help

Klonaza overdose is officially documented to carry risks related to its components, primarily the NSAID, requiring specific emergency responses.

Documented Overdose Presentations: Overdose manifestations may include CNS effects such as drowsiness, confusion, lethargy, vertigo, and headache. Gastrointestinal symptoms like abdominal pain, nausea, and vomiting are commonly listed. Cardiovascular signs like hypotension and tachycardia may also be present. Cases involving the antispasmodic component have been reported without specific symptomatology.

Severe and Life-Threatening Outcomes: Official regulatory documents classify severe overdose as having the potential for life-threatening outcomes. These include Gastrointestinal Hemorrhage, ulceration, and perforation, as well as Acute Renal Insufficiency. In the most severe cases, convulsions and coma have been reported.

When Immediate Medical Help is Required: Regulatory guidance strictly mandates that individuals seek immediate emergency help or contact a Poison Control Center right away for any suspected overdose. Immediate medical attention is specifically required upon the development of signs of severe adverse events, such as bloody stools (melena), vomiting blood, or sudden swelling, especially in those over 60 years of age. The risk of serious GI and renal effects is documented to be higher in the elderly and in patients with pre-existing renal or hepatic impairment.

Official Management and Antidote Status: Overdose management is limited to symptomatic and supportive treatment, with official documents stating that no specific antidote is known. This supportive care involves close monitoring of vital signs and assessment of renal function.

Therapeutic Uses of Klonaza

What Klonaza Treats: Main Uses and Benefits

The primary role of this medication is commonly used to help with situations involving symptoms of increased neurological or muscular activity and heightened physiological activity. The medication is generally used across therapeutic domains where short-term symptom management is appropriate, particularly for seizures, Panic Disorder, and certain involuntary movement conditions.

Klonaza is applied in clinical settings that involve acute or unstable symptom patterns, especially during phases when symptoms become temporarily overwhelming. It is relevant for easing distressing manifestations of fear and dread and may assist with managing involuntary movements like muscle spasms.

“It offers symptomatic relief that may assist with coping during difficult episodes.”

This supportive therapeutic benefit may assist with managing the frequency and intensity of episodes and contributes to maintaining functional stability.


Quick Fact: Support for Acute Psychological Distress Symptoms

Regulatory References

  1. NIH MedlinePlus overview of Clonazepam

Eligibility and Restrictions for Use

Who Can and Cannot Use Klonaza?

Regulatory documents define strict population eligibility for Klonaza, a fixed-dose combination.

Eligibility Scope Official Regulatory Status
Populations Allowed Adults (18 years and older) who meet all other criteria.
Populations Contraindicated Must not use if known hypersensitivity to any component.
Specific Conditions Contraindicated Use is prohibited in patients with severe renal or hepatic impairment and a history of gastrointestinal bleeding or peptic ulcers. The drug is also prohibited with functional ileus or intestinal obstruction.
Pregnancy Contraindicated in the third trimester. Conditional use only in the first and second trimesters.
Lactation Not recommended for breastfeeding women, particularly those nursing newborns, due to insufficient safety data.
Pediatric Use Safety and efficacy for the fixed-dose combination are not established in children and adolescents.

The official labeling defines eligibility based on the combined risk profile of the components, specifically restricting use based on organ function, GI pathology, and reproductive status. Eligibility is established only in the adult population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation details the specific interaction patterns for Klonaza, a fixed-dose combination containing an NSAID component (Clonixin) and a spasmolytic component (Phloroglucinol).

Documented Interaction Categories

Pharmacodynamic Restrictions: Co-administration with Major Analgesics such as Morphine and Morphine Derivatives should be avoided. This restriction is based on the documented spasmogenic effect of opioids, which functionally opposes the spasmolytic action provided by the Phloroglucinol component.

Exposure-Modifying Substances: The NSAID component can increase the plasma concentrations of certain co-administered drugs by reducing their renal clearance. This applies to substances such as Lithium and Methotrexate, which require regulatory caution upon co-administration to manage exposure levels.

Hemorrhagic Risk and Efficacy Reduction: The NSAID class effect dictates that concomitant use with Oral Anticoagulants is associated with an increased risk of bleeding and hemorrhage. Furthermore, the antihypertensive and natriuretic effects of ACE Inhibitors, ARBs, and Diuretics may be diminished when co-administered. The regulatory profile also notes that combining the NSAID component with antihypertensives in the elderly or those with existing renal impairment may lead to a deterioration of renal function.

Mechanism of Action

Klonaza (clonazepam) functions by directly targeting the inhibitory neurotransmission system in the central nervous system (CNS), specifically acting as a positive allosteric modulator (PAM) of the gamma-aminobutyric acid type A (GABAA) receptor complex.

Molecular Interaction and Cascade

Klonaza binds to a distinct allosteric site on the GABAA receptor, thereby enhancing the effect of the endogenous inhibitory neurotransmitter GABA. This interaction increases the frequency of chloride ion channel opening. The resulting influx of negatively charged chloride ions induces neuronal hyperpolarization, which is the foundational cellular event in reducing overall neuronal excitability.

System-Level Modulation

This molecular cascade leads to a selective enhancement of the CNS inhibitory tone relative to excitatory activity. The mechanism supports a shift toward regulated network activity, which reduces the propensity for sustained, synchronous neuronal depolarization. This augmented inhibition is particularly relevant in areas like the limbic system and cerebral cortex, where its presence results in the attenuation of heightened limbic and cortical signaling, thereby influencing patterns of autonomic and motor response.

Dosage and Administration Information

Klonaza is utilized according to specific administration guidelines. The medication is supplied as an oral tablet and an injectable solution, supporting oral use as well as parenteral administration routes, including Intramuscular (IM) and Intravenous (IV) injection. The oral tablet is administered on an as-needed (PRN) basis when acute symptoms occur.

For adults, the standard dose is 2 tablets taken at the time of the episode. Dosing must be repeated only after a mandatory minimum interval of 2 hours has passed, and the total daily intake is strictly limited, not exceeding 6 tablets per 24 hours. The tablet can be administered by dissolving it under the tongue (sublingually) or by dissolving it in a glass of water prior to ingestion.

Specific administration rules apply to pediatric patients. Children over 2 years of age are administered 1 tablet per episode, adhering to the same 2-hour minimum interval, with a maximum limit of 2 tablets per 24 hours. For this age group, the tablet must be dissolved in water before administration. The overall use pattern is for symptomatic treatment, and continued use requires clinical reassessment if the acute symptoms persist or fail to improve. These administration protocols define the standardized approach to using the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Klonaza

Evidence Supporting the Dual Action in Pain and Spasm Relief

This section will summarize the types of pharmacological studies and clinical research that have been conducted to evaluate Klonaza's integrated approach in research contexts involving the co-occurrence of physical discomfort and involuntary smooth muscle contractions. The content will include a summary of the outcomes and symptoms that were measured in these trials.

Research has been used in research exploring how symptoms change over time and was applied in studies examining patient-reported experiences relevant in research contexts involving fluctuating or unstable symptoms. Studies describe measurements taken related to changes in both the sensation of pain and the degree of underlying muscle tension. The research also reports how symptoms evolved in the observed populations concerning patient-reported outcomes describing perceived discomfort and functional stability. These studies provide insight into short-term changes used in studies examining symptom intensity or variability.

Studies on the Individual Active Components

This section will detail the scientific research that established the distinct role of each active ingredient: the Nonsteroidal Anti-inflammatory Drug (NSAID) component (Clonixin) and the spasmolytic components (Phloroglucinol and Trimethylphloroglucinol). It will describe the research that explored the integrated action of these components, which was associated with the potential for simultaneous evaluation of symptoms.

Specific pharmacological studies was evaluated in the distinct roles of the active ingredients within Klonaza. Research examined the Nonsteroidal Anti-inflammatory Drug (NSAID) component, Clonixin, for its contribution related to outcomes linked to physical discomfort.

Follow-up Duration and Length of Studies

Clinical studies conducted so far have primarily been applied in studies examining patient-reported experiences relevant in trials assessing short-term or episodic symptom patterns. The majority of evidence reflects how symptoms evolved in the observed populations during research conducted in settings with varying symptom burdens or acute episodes.

There is currently limited information for long-term outcomes regarding the use of Klonaza. Observed changes over extended time intervals are not fully established, as research primarily focused on research exploring short-term symptom changes.

What Is Still Uncertain About Klonaza Research

The data for certain patient characteristics, such as specific symptom intensity groups or individuals with certain comorbidities, remain insufficient. This means that study results reflect the specific conditions under which they were conducted, and research does not determine individual response.

Key Studies & References Fixed dose combination, a model therapy optimization strategy: A review (Contextual support for FDC rationale and design)

Frequently Asked Questions (FAQ)

Common questions about Klonaza (FAQ)

Q: How quickly should I expect to feel the effects of Klonaza after taking it?

A: Regulatory resources indicate the medication, Clonazepam, has a rapid onset of action. While some initial relief may be noted quickly, achieving the full, consistent effect may require continued use over a certain period.


Q: How long does the effect of one dose of Klonaza typically last?

A: Regulatory pharmacokinetic data for Clonazepam show it has a long elimination half-life, ranging from approximately 19 to 60 hours. This measure indicates the time required for half of the medication to be eliminated from the body.


Q: What happens if you miss a dose of Klonaza?

A: Official patient instructions generally advise taking the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. This helps ensure that the dosing interval is maintained.


Q: Are there any non-prescription products or supplements that interact with Klonaza?

A: Official labeling advises consulting a healthcare provider about all substances taken, as non-prescription products, vitamins, and supplements have the potential to interact with the medication. Patients should inform their team about everything they take.


Q: Are there any specific cold or flu medicines that interact with Klonaza?

A: Regulatory information advises caution with any medicines that cause sleepiness or dizziness. Since many common cold and flu remedies contain ingredients that cause drowsiness, combining them with this medication may increase the risk of intensified side effects.


Q: Can Klonaza be used for muscle spasms or restless legs syndrome?

A: Due to its mechanism, the medication Clonazepam is sometimes used in research or clinical settings to help manage symptoms associated with restless legs syndrome and muscle spasms. Its use is determined by a healthcare provider.


Q: Is Klonaza a controlled substance in the US/UK/other regions?

A: The medication Clonazepam is classified by the DEA as a Schedule IV controlled substance under the U.S. Federal Controlled Substances Act. This classification reflects its potential for abuse, misuse, and dependence.


Q: Is there recent research evidence supporting the use of Klonaza for anxiety?

A: The official FDA indication for Clonazepam is for the management of panic disorder, a condition classified within the anxiety disorders spectrum. The drug is often studied in contexts related to panic and anxiety symptom reduction.


Q: Does Klonaza have any effect on blood pressure?

A: Hypotension (low blood pressure) is noted as a rare side effect in some authoritative resources. Any concerns about blood pressure should be discussed with a healthcare provider.


Q: What should I do if a common side effect of Klonaza doesn't go away?

A: Official information advises contacting a healthcare provider for medical advice regarding side effects that are severe or persist. Discontinuation should always be managed under professional supervision, as stopping abruptly can lead to withdrawal.


Q: Are there specific times of day that are better for taking Klonaza?

A: The timing of the dose is a decision made by the healthcare provider. For some indications, the dose may be split and taken twice per day. In other cases, it may be advised to take the dose at bedtime to help manage certain side effects like drowsiness.


Q: Can Klonaza be safely taken by someone who has asthma?

A: Official information advises caution or careful use in individuals with pre-existing lung or breathing diseases, such as asthma or chronic respiratory insufficiency. The safety of the medication in this context requires assessment from a healthcare provider.


Q: What are the main differences between the generic and brand name versions of Klonaza?

A: The FDA requires that the generic version of the drug, Clonazepam, be bioequivalent to the brand name (Klonopin). This means the generic version contains the same active ingredient and is expected to work in the same way, providing the same clinical benefits.


Q: Does Klonaza interfere with driving or operating heavy machinery?

A: Official warnings indicate the medication produces CNS depression. Patients are advised to use caution when engaging in hazardous activities, such as driving a motor vehicle or operating heavy machinery, until they know how the drug affects them.


Q: Why do doctors often prescribe Klonaza for a short period of time?

A: Regulatory labeling includes a Boxed Warning regarding the risks of abuse, misuse, addiction, and physical dependence. The risk is known to increase with longer treatment duration, and this warning guides the practice of limiting the duration of use.


Q: Is it normal to have vivid dreams or nightmares when taking Klonaza?

A: Yes, vivid dreams and nightmares have been reported with the use of this class of medication. These are sometimes described as 'paradoxical reactions,' or effects that are unusual for a drug that depresses the central nervous system.


Q: Can Klonaza cause skin rash or allergic reaction?

A: Official patient information lists symptoms of a serious allergic reaction, which include a skin rash or hives. If these or any other severe allergic symptoms appear, patients should seek immediate medical attention.


Q: What studies exist regarding the long-term use of Klonaza?

A: Regulatory documents refer to studies on long-term use primarily due to concerns about the risk of physical dependence. Research has also explored reports of persistent cognitive deficits, including memory impairment, associated with extended use.


Q: Do you need to taper off Klonaza, or can you just stop taking it?

A: Patients are officially warned not to stop taking the medication abruptly without first consulting their healthcare provider. Abrupt discontinuation can lead to severe life-threatening acute withdrawal reactions. Discontinuation should be managed under professional supervision, often involving a gradual reduction in dosage.


Q: How long does Klonaza stay in your system?

A: The elimination half-life for Clonazepam is approximately 19 to 60 hours. While the half-life is an indicator of how long the medicine takes to leave the body, its effects on the central nervous system may persist.


Q: Can Klonaza be used during pregnancy or while breastfeeding?

A: Official information states that use during pregnancy can cause harm to an unborn baby, and prolonged use can lead to temporary withdrawal symptoms in the newborn. The medication can also pass into breast milk. Decisions regarding use during pregnancy or breastfeeding should always be made in consultation with a healthcare provider.


Q: Is it true that Klonaza can sometimes cause increased irritability in some people?

A: Yes, reports indicate that some individuals experience irritability and unusual changes in mood or behavior while taking this medication. These are considered paradoxical reactions.


Q: How do I know if Klonaza is actually helping my condition?

A: Patients are generally advised to have regular checks with their healthcare team to assess progress. Patients should inform their healthcare team if symptoms are not improving or if they worsen.


Q: Does Klonaza interact with birth control pills?

A: As an Antiepileptic Drug (AED), this medication may have complex interactions with hormonal contraceptives (birth control pills). These interactions could potentially decrease the effectiveness of the birth control. Patients taking hormonal contraceptives should seek professional guidance regarding appropriate contraceptive methods.


Q: Is it safe to use Klonaza if I have a history of glaucoma?

A: The drug is officially contraindicated (must not be used) in patients with acute narrow angle glaucoma. However, it may be used in patients who have open-angle glaucoma and are receiving appropriate treatment.


Q: What are the specific receptors in the brain that Klonaza targets?

A: The medication is a benzodiazepine, which acts by enhancing the effect of the inhibitory neurotransmitter known as GABA (gamma-aminobutyric acid). It achieves this by binding to the GABAA receptors in the brain.


Q: Does alcohol make the side effects of Klonaza worse?

A: Yes, official warnings state that using the medication with alcohol can significantly increase nervous system side effects such as drowsiness and dizziness. Combining them can intensify CNS depression, leading to profound sedation and severe respiratory risk.


Q: Why is Klonaza sometimes prescribed for conditions other than anxiety?

A: In addition to panic disorder, the drug Clonazepam is officially indicated for the treatment of certain types of seizure disorders. This dual indication explains why it is prescribed across different medical conditions.


Q: Is Klonaza considered an anti-anxiety medicine or a sleep aid?

A: The medication Clonazepam is officially indicated for the management of panic disorder and certain seizure disorders. While drowsiness is a common side effect, it is not officially indicated or approved as a primary sleep aid.


Q: How is Klonaza different from similar medications like [Similar Drug Name]?

A: The specific drug Klonaza is a unique Fixed-Dose Combination (FDC) that contains an NSAID (Clonixin) and Spasmolytic components. This dual action in a single pill is its main differentiating feature compared to single-agent pain or spasm medications.


Q: What are the most common side effects of Klonaza that people experience?

A: Based on clinical trial data, the most frequently reported side effects include drowsiness, problems with walking and coordination (ataxia), dizziness, depression, fatigue, and problems with memory.


Q: Does Klonaza cause drowsiness or tiredness?

A: Yes, drowsiness (somnolence) and fatigue are explicitly listed in official product information as being among the most common adverse reactions reported by patients.


Q: Can taking Klonaza affect your memory long-term?

A: Memory disturbance is a common side effect reported with this medication. Furthermore, long-term use has been associated with reports of persistent cognitive deficits, including memory impairment.


Q: Is it safe to take Klonaza if I am also taking an antidepressant?

A: This medication carries a general increased risk of suicidal thoughts or behavior, and patients should be monitored for the emergence or worsening of depression. Any co-administration with antidepressants requires professional assessment to manage the overall risk profile.


Q: What types of food should I avoid while taking Klonaza?

A: Official information strongly advises patients to avoid alcohol due to the risk of severe CNS depression. While specific foods are not generally listed for avoidance, patients should discuss all dietary concerns with their healthcare provider.

How should Klonaza be stored and disposed of?

Storage Requirements

Klonaza must be stored at a controlled temperature, specifically below 30 C. To maintain product integrity, the medicine must be kept in its original package to ensure protection from moisture. Any bottle must be kept tightly closed after use. For safety, Klonaza must be stored out of the sight and reach of children.

Stability and Handling

The medicine must not be used after the expiry date printed on the packaging. If the medicine is supplied in an openable bottle, the contents typically should be used within 1 month of the first opening.

Disposal Instructions

Unused or expired Klonaza must not be disposed of by throwing it away with household waste or pouring it down wastewater. Official instructions require users to ask a pharmacist for the proper procedure to throw away medicines you no longer use. These methods are essential to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Klonaza found in:

A-Z Index: